Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14678180 | 0.80 | HSP90AA1 (0.40) | HSP90AA1P2RX7KCNH3 | |
| SCHEMBL1444665 | 0.80 | HSP90AA1 (0.40) | HSP90AA1P2RX7NAMPTKCNH3FAAH | |
| SCHEMBL10187739 | 0.77 | P2RX7 (0.41) | HSP90AA1P2RX7NAMPTKCNH3FAAH | |
| SCHEMBL27791197 | 0.75 | — | — | |
| SCHEMBL8051975 | 0.75 | — | — | |
| SCHEMBL4661605 | 0.75 | — | — | |
| SCHEMBL45811 | 0.75 | — | — | |
| SCHEMBL1525817 | 0.73 | HRH1 (0.45) | — | |
| SCHEMBL9527267 | 0.73 | HRH1 (0.45) | — | |
| Hydrochloric Acid SCHEMBL8754865 | 0.72 | LMNA (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2322518-B1 | Method of manufacture of 1,3-dioxolane and 1,3-oxathiolane nucleosides | GILEAD SCIENCES INC (US) | 2015-02-25 | — | — | EP | claimed |
| US-20140121186-A1 | Compounds, Compositions and Methods for Treating Ocular Conditions | CHIMERIX, INC. (US) | 2014-05-01 | — | — | US | claimed |
| WO-2011011519-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OCULAR CONDITIONS | CHIMERIX, INC. (US) | 2011-01-27 | — | — | WO | claimed |
| US-7230100-B2 | Stereoselective method for the preparation of nucleosides | SHIRE BIOCHEM., INC. (CA) | 2007-06-12 | — | — | US | claimed |
| EP-1406896-B8 | STEREOSELECTIVE METHOD FOR THE PREPARATION OF NUCLEOSIDE ANALOGUES | SHIRE BIOCHEM INC (CA) | 2006-11-15 | — | — | EP | claimed |
| US-7109334-B2 | Stereoselective methods for the preparation of nucleosides | SHIRE BIOCHEM, INC. (CA) | 2006-09-19 | — | — | US | claimed |
| US-20060183899-A1 | Stereoselective method for the preparation of nucleosides | YU QING | 2006-08-17 | — | — | US | claimed |
| EP-1632490-A1 | STEREOSELECTIVE METHOD FOR THE PREPARATION OF NUCLEOSIDE ANALOGUES | Shire Biochem Inc. (CA) | 2006-03-08 | — | — | EP | claimed |
| EP-1406896-B1 | ATEREOSELECTIVE METHOD FOR THE PREPARATION OF NUCLEOSIDE ANALOGUES | SHIRE BIOCHEM INC (CA) | 2005-12-21 | — | — | EP | claimed |
| US-6939965-B2 | Process of manufacture of 1,3-oxathiolane nucleosides using titanium trichloride mono-isopropoxide | GILEAD SCIENCES, INC. (US) | 2005-09-06 | — | — | US | claimed |
| EP-1406896-A1 | ATEREOSELECTIVE METHOD FOR THE PREPARATION OF NUCLEOSIDE ANALOGUES | Shire Biochem Inc. (CA) | 2004-04-14 | — | — | EP | claimed |
| US-20030135048-A1 | Stereoselective methods for the preparation of nucleosides | SHIRE BIOCHEM INC. (CA) | 2003-07-17 | — | — | US | claimed |
| US-6518425-B1 | A process for producing a 1,3-oxathiolane nucleoside comprising reacting a 5-halo-2-protected-oxymethyl-1,3-oxathiolane with a silylated purine or pyrimidine without the addition of a Lewis acid or an additional base to the reaction | EMORY UNIVERSITY | 2003-02-11 | — | — | US | claimed |
| US-20030013880-A1 | Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers | APOTEX PHARMACHEM INC (CA) | 2003-01-16 | — | — | US | claimed |
| WO-2002102796-A1 | STEREOSELECTIVE METHOD FOR THE PREPARATION OF NUCLEOSIDE ANALOGUES | SHIRE BIOCHEM INC. (CA) | 2002-12-27 | — | — | WO | claimed |
| US-20170333459-A1 | METHODS OF TREATING ORTHOPOX VIRUS INFECTIONS AND ASSOCIATED DISEASES | CHIMERIX, INC. | 2017-11-23 | — | — | US | disclosed |
| EP-2012799-B1 | METABOLICALLY STABLE ALKOXYALKYL ESTERS OF ANTIVIRAL OR ANTIPROLIFERATIVE PHOSPHONATES, NUCLEOSIDE PHOSPHONATES AND NUCLEOSIDE PHOSPHATES | CHIMERIX INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-6215004-B1 | CYCLIZATION OF MERCAPTOACETIC ACID WITH ACETAL IN SOLVENT; SULFIDING | EMORY UNIVERSITY | 2001-04-10 | — | — | US | disclosed |
| WO-2000009531-A2 | β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | NOVIRIO PHARMACEUTICALS LIMITED (KY) | 2000-02-24 | — | — | WO | disclosed |
| WO-2000009494-A1 | METHOD OF MANUFACTURE OF 1,3-OXATHIOLANE NUCLEOSIDES | TRIANGLE PHARMACEUTICALS, INC. (US) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121186-A1 | Compounds, Compositions and Methods for Treating Ocular Conditions | EYA3, EYA2, PDE6C | HSP90AA1 4271/4885P2RX7 158/4885NAMPT 1146/4885 |
| US-20030013880-A1 | Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers | SLC29A1, NUDT1, SLC28A1 | HSP90AA1 3320/4885P2RX7 2728/4885NAMPT 73/4885 |
| US-20030135048-A1 | Stereoselective methods for the preparation of nucleosides | DPYD, PNP, SLC29A1 | HSP90AA1 3622/4885P2RX7 1263/4885NAMPT 203/4885 |
| US-20060183899-A1 | Stereoselective method for the preparation of nucleosides | DPYD, PNP, ADAR | HSP90AA1 4108/4885P2RX7 1131/4885NAMPT 135/4885 |
| US-20170333459-A1 | METHODS OF TREATING ORTHOPOX VIRUS INFECTIONS AND ASSOCIATED DISEASES | OAT, PNPO, OTC | HSP90AA1 911/4885P2RX7 128/4885NAMPT 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.